Celera's Q4 Revenues Increase 15 Percent; Swings to Loss

Celera's revenues were driven by sales of its KIF6 testing service, but the firm posted a loss for the second quarter in a row on higher SG&A spending related to building its infrastructure following its split from Applera.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.